Supplement: MilliporeSigma Sees Opportunity in Continuous Processing
From the GEN Sounds of Science Podcast
Why CAR-T Therapies Don’t Work for Everyone Yet
Selecting the Best Type of T Cells for CAR-T May be Key to the Overall Efficacy of the Therapies
Cell-Centered: Scientists Embrace Cell-Replacement Therapy for Type 1 Diabetes
Forming Beta Cells from Stem Cells
GEN Roundup: Multiplex Immunoassays Bring the Array, Not the Disarray
Get Multiplex Immunoassay Advice from GEN's Expert Panel
For full access to this article login to GEN Select now.
De-Risking Clinical Development
Best Bet May Be to Repurpose a Well-Defined Drug with Proven Safety and Utility in Humans
- Taking a drug from the laboratory and preclinical testing arena into first-in-human studies and clinical trials represents the largest, most costly gamble in the drug discovery pipeline. During this phase of development patient safety takes center stage and acquires quantifiable parameters, dosing may require some guesswork and trial-and-error, ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.